Cart
sales@molnova.com
Survodutide
CAS No. 2805997-46-8
Survodutide( —— )
Catalog No. M36653 CAS No. 2805997-46-8
Survodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 217 | In Stock |
|
| 10MG | 330 | In Stock |
|
| 25MG | 548 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSurvodutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionSurvodutide (BI 456906) is a dual agonist of glucagon and glucagon-like peptide 1 (GLP-1) receptors (GLP Receptor) that reduces body weight in HbA1c16 diabetes.
-
DescriptionSurvodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
-
In Vitro——
-
In VivoAnimal Model:Male C57BL6/J mice pre-fed with a 60% HFD (22 weeks)Dosage:3, 10, 20, 30 nmol/kg Administration:SC; daily; 30 days Result:Dose-dependently reduced bodyweight from baseline by up to 32% at Day 28 at a dose of 30 nmol/kg.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2805997-46-8
-
Formula Weight4231.62
-
Molecular FormulaC192H289N47O61
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (23.63 mM; Ultrasonic )
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tina Zimmermann, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022 Dec:66:101633. ?
molnova catalog
related products
-
HAEGTFTSD
HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
-
GLP-1R agonist 3
GLP-1R agonist 3 is a potent imidazole derivative and GLP-1R agonist with demonstrated research potential in diabetes. [Thickened]
-
PF-06882961 Tris
PF-06882961 Tris is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist.
